
RSV Raises Risk for Diverse Complications Across Adulthood
In a study of nearly 45,000 individuals published online in Influenza and Other Respiratory Viruses , Wang Chun Kwok, MD, of the University of Hong Kong, Hong Kong, and colleagues compared data from 41,206 adult patients hospitalized with flu and 3565 hospitalized for RSV infections at centers in Hong Kong.
Overall, patients with RSV infection had significantly higher risk not only for in-patient mortality but also severe respiratory failure, secondary bacterial pneumonia, and acute kidney injury than patients with flu ( P < .001 for all).
In addition, the researchers highlighted end-stage kidney disease requiring renal replacement therapy as a significant independent risk factor for poor outcomes among the RSV patients, with an adjusted odds ratio of 4.74 for in-hospital mortality ( P < .001).
The patients with RSV infection also were stratified by age based on current US recommendations for RSV vaccination (aged 60 years and older, younger than 60 years, and 50-59 years).
Notably, the findings of increased risk were consistent across all adult age groups, the researchers wrote. 'The risk factors for severe RSV infections demonstrated in this study provided insights on the target patient subgroups for vaccination, especially among countries and places with limited resources that do not allow vaccination for the entire population,' they concluded.
Flu vs RSV
The study by Kwok and colleagues provides an essential comparison, said Seyedmohammad Pourshahid, MD, assistant professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, Philadelphia, in an interview.
'For decades, influenza has set the standard in how we talk about vaccine-preventable adult respiratory disease, but with RSV vaccines now entering clinical use, it's critical to understand whether RSV deserves similar attention,' he said.
'The findings speak to more than just respiratory illness. The added burden of renal complications and secondary infections makes it clear that RSV can be a systemic threat, especially in hospitalized adults,' said Pourshahid. What stands out is that this pattern was seen across a range of adult ages, not just in the elderly, which challenges the current boundaries we draw around vaccine eligibility,' he added.
Limitations of the study include not only the retrospective design but also the impact of variables including coding accuracy, variability in care, and the effect of existing vaccine use for influenza, which all play a role in shaping outcomes, said Pourshahid. However, the consistent trends seen in the study point toward a need to reevaluate RSV prevention, he said.
'From a clinical perspective, this means not underestimating RSV, especially in patients with kidney or cardiopulmonary disease. From a public health perspective, it raises the question of whether our current vaccine recommendations are too narrow,' Pourshahid told Medscape Medical News . 'With further data, particularly post-vaccine implementation, we may find that the case for broader immunization is stronger than expected,' he said.
Additional studies should follow vaccinated patients to identify any changes in the patterns of complications, Pourshahid said. 'These kinds of real-world data will be essential in helping us understand not just whether the vaccine prevents RSV infection, but whether it also reduces the broader complications that come with it,' he said.
In another study, published in Clinical Infections Diseases, Paulina Sudnik, MD, of the University of Rochester, Rochester, New York, and colleagues found that approximately one-third of 471 adults hospitalized with RSV experienced a cardiovascular event (CVE) during the high-risk period of the first 28 days after hospital admission.
Previous studies support an association between respiratory viral infections such as influenza and COVID-19 and acute CVEs, but data on the patients with CVEs in the context of RSV are lacking, the researchers wrote.
The study population included 471 adults aged 18 years and older who were hospitalized for at least 24 hours with RSV. Overall, 174 of the patients (37%) experienced a total of 270 CVEs during the high-risk period. The most common CVE was congestive heart failure (25%), followed by atrial fibrillation or flutter (13%), and myocardial infarction (9%).
Although 44% of the CVEs occurred in patients with no prior history of CVEs, preexisting conditions including hypertension, congestive heart failure, atrial fibrillation, and coronary artery disease, or evidence of at least three classic cardiac risk factors were significantly associated with increased CVE risk among patients older than 65 years.
Additionally, the monthly incidence of CVE after RSV infection was significantly increased compared to the pre-infection period, with incidence rate ratios of 18.5 and 1.6 during the high-risk and low-risk periods, respectively, compared to the pre-RSV period.
The study was limited by several factors, including the retrospective design and a lack of data on subclinical cardiac injury and CVEs that were mild or occurred outside the hospital setting.
However, the results were strengthened by the comparison of CVE data before and after RSV hospitalization, and the data may inform clinical decision-making on RSV vaccination, the researchers concluded.
Translating Data Into Practice
The study by Sudnick and colleagues brings needed attention to a dimension of RSV that is often overlooked, Pourshahid said in an interview.
'While most clinical focus has been on its respiratory manifestations, this work shifts the lens to cardiovascular complications and raises important questions about who is truly at risk and how those risks unfold,' he said. 'The fact that many of the events occurred in people without known heart disease adds weight to the idea that RSV can act as a stressor, revealing latent disease or perhaps even provoking new events through inflammation and hemodynamic strain,' he added.
Several limitations prevent drawing broad conclusions from the study, Pourshahid told Medscape Medical News . 'The data come from a specific region and rely on retrospective review, which limits how far we can generalize, and hospitalized patients also tend to be monitored more closely, so we may be picking up events that would otherwise go unnoticed,' he said. However, these limitations don't detract from the message that the RSV's impact is wider than clinicians might often consider, he added.
Clinically, the data reinforce the importance of paying close attention to the cardiovascular profile of patients admitted with RSV, even those without known cardiac disease, and contribute to conversations among policy makers and vaccine and vaccine developers, he noted. 'Preventing RSV might mean preventing not just respiratory failure but also heart failure, arrhythmias, or ischemic events, which is an important shift in how we think about vaccine value,' he said.
Prospective studies that can look more closely at how these events happen, how often they recur, and whether vaccines can interrupt that trajectory,' Pourshahid said.
'As this study took place before RSV vaccines became available, we are in a key moment to begin tracking how the clinical picture changes in vaccinated populations,' he said.
Kwok and Desmond Yat Hin Yap disclosed receiving research support from GlaxoSmithKline.
The study by Sudnik and colleagues received no outside funding. Sudnik disclosed having no financial conflicts.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
BEIJING, July 28, 2025--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a comprehensive upgrade to its preclinical business division. The upgrade features an expanded portfolio of genetically engineered animal models—including target-humanized, immune-humanized, transgenic, and immunodeficient mice—alongside a full suite of preclinical services such as efficacy studies, PK/PD analysis, biomarker evaluation, and non-GLP toxicology testing. In parallel, the company also launched its new official website ( featuring an intuitive structure, enriched content, and an optimized multilingual user experience to serve global clients and partners better. Extensive Model Portfolio with Over 1,100 Target-Humanized Mouse Models In 2021, Biocytogen launched the "BioMice" sub-brand to advance its portfolio of genetically engineered mouse models. Leveraging its proprietary gene-editing platform, the company has developed more than 1,100 target-humanized mice. These models are generated using precise in situ gene replacement technology, which substitutes mouse genes with human sequences while preserving endogenous gene regulation. This approach enables a more accurate simulation of human physiological and pathological conditions, establishing BioMice as the gold-standard platform for evaluating the efficacy and safety of various therapeutic modalities, including antibody drugs, cell therapies, bispecific/multispecific antibodies, ADCs, and oligonucleotide-based treatments. The company has established high-value disease models for oncology, autoimmune, metabolic, and neurological disorders, including CD3 (TCEs), HER2 (TAAs), TL1A (IBD), TSLP (AD), GLP1R (muscle gain/weight loss), and TFR1 (BBB delivery). These models are widely used for target validation, mechanistic studies, and preclinical evaluations. To date, safety data generated from these models have supported 15 IND approvals by China's NMPA and 5 IND approvals by the U.S. FDA (including 4 dual submissions). Biocytogen also offers immune-humanized mouse models (e.g., huPBMC-B-NDG, huHSC-B-NDG, huHSC-B-NDG hIL15, and huPBMC-B-NDG MHC I/II DKO plus), transgenic mice, and immunodeficient strains to support evaluations of immuno-oncology agents, T/NK cell therapies, and immunostimulatory drugs, building a comprehensive and multi-dimensional model portfolio. Global Animal Supply Network Supporting Efficient Preclinical Research Biocytogen operates three AAALAC-accredited animal facilities in Haimen (Jiangsu), Daxing (Beijing), and Boston (USA), covering a total area of 55,000 m² and offering an annual supply capacity of over 800,000 laboratory animals. With a robust quality control system and standardized microbial monitoring, Biocytogen has established an international distribution network spanning Asia, Europe, and North America. The company's mouse models have been successfully delivered to clients in over 20 countries and regions, providing reliable model support for global drug development efforts. Integrated Preclinical Services to Accelerate IND Filing and Clinical Translation Leveraging its proprietary animal models, Biocytogen provides one-stop, non-GLP preclinical products and services, including in vivo efficacy testing, PK/PD analysis, biomarker assessment, and early toxicology studies. With a vast collection of CDX and PDX tumor models and customizable study designs, Biocytogen serves over 20 therapeutic areas—including solid tumors, hematologic malignancies, autoimmune diseases, metabolic disorders, and neurodegenerative diseases—and supports a variety of drug modalities such as antibodies, small molecules, ADCs, bispecifics, cell therapies, nucleic acids, and vaccines. As of now, Biocytogen has completed more than 5,300 drug evaluation studies for nearly 900 pharmaceutical and academic institutions worldwide. Over One Million Fully Human Antibodies Empowering Antibody Drug Discovery Beyond preclinical services, Biocytogen also leads in antibody discovery through its proprietary RenMice® platforms—including RenMab™ (fully human antibody), RenLite® (common light chain), RenNano® (VHH antibody), RenTCR™ (fully human TCR), and RenTCR-mimic™ (fully human TCR-mimic antibody). The company has built a library of over one million fully human antibody sequences against more than 1,000 potential therapeutic targets, with diverse structures and functional profiles. As of December 31, 2024, Biocytogen has signed approximately 200 drug co-development, licensing, or transfer agreements, including over 50 target-based RenMice® platform collaborations with multinational pharmaceutical companies. Multiple clinical-stage antibody candidates have also been successfully out-licensed to global partners. Biocytogen's integrated capabilities in antibody discovery, screening, and engineering are accelerating the transition from target validation to clinical candidate selection, empowering global biopharmaceutical innovation. New Official Website Launched to Serve Global Clients To enhance global service capabilities, Biocytogen has officially launched its new website: Designed for a clean and intuitive user experience, the new site features streamlined architecture, upgraded content organization, improved search functionality, and multilingual support in Chinese, English, Japanese, and Korean. Structured around its two main business divisions—BioMice® for preclinical products and services and RenBiologics™ for antibody discovery and collaboration—the site offers a comprehensive overview of Biocytogen's model products, antibody assets, project portfolios, and service capabilities. It provides an efficient and direct information portal for global partners and supports the company's ongoing internationalization strategy. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab™/ RenLite®/ RenNano®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit View source version on Contacts Biocytogen Contacts Preclinical Products and Services: info@ Antibody assets and platforms: BD-Licensing@ Media: pr@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Medscape
an hour ago
- Medscape
Patients With Acromegaly Face Higher Cancer Risk
TOPLINE: Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention. METHODOLOGY: Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known. Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition. Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition. TAKEAWAY: Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8). The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population. IN PRACTICE: 'Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,' said the lead researcher in a press release. SOURCE: This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco. LIMITATIONS: This study did not report any specific limitations. DISCLOSURES: This study did not report any specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.


Medscape
an hour ago
- Medscape
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.